Storing dried blood spots in NL

Slides:



Advertisements
Similar presentations
DSHS Texas Newborn Screening Program Processes Susan Tanksley, PhD David Martinez April 10, 2008.
Advertisements

Day 2 You receive 2 reports on your desk –The first describes the possibility of expanding the states newborn screening panel to include Severe Combined.
The Human Tissue Act and You Steve Hopkins Designated Individual for Research Tissue
Storage, Retention, and Use of Residual Dried Blood Spots Storage, Retention, and Use of Residual Dried Blood Spots Harry Hannon, PhD and Brad Therrell,
The need for screening newborns for congenital Cytomegalovirus referred in the Neonatal Hearing Screening Program F.A.J. Schornagel 1, M.J. Korndewal 1,
Treuman Katz Center for Pediatric Bioethics Conference Newborn Screening: The Future Revolution Beth A. Tarini, MD, MS Assistant Professor Child.
Newborn Screening Overview Marie Mann, M.D., M.P.H. U.S. Department of Health and Human Services Health Resources and Services Administration Maternal.
Health manpower and newborn screening Joann Bodurtha MD MPH.
Prepared by Jane Hibbert on behalf of the Regional ANCH Screening Teams Expanded Newborn Screening Pilot 16th July 2012 – 19th July 2013 NIHR CLAHRC for.
August 2006 Newborn Screening Programmes. Introduction These slides bring you up to date with the three NSC Newborn Screening Programmes The Blood Spot.
Protecting Participants in a Global Research Community Dr. Jane Kaye University of Oxford, UK.
EMGO Institute for Health and Care Research Quality of Care Martina Cornel, MD, PhD, professor of Community Genetics & Public Health Genomics PPPC activities.
The National Academies’ Board on Life Sciences Dr. Frances Sharples Director National Research Council National Research Council.
Be a Public Health Nurse
EMGO Institute for Health and Care Research Quality of Care Martina Cornel, MD, PhD Professor of community genetics & public health genomics Genetic screening.
Libyan-UK partnership on Infectious Diseases Control Professor Abdulhafid A. Abudher MBBch,DGO,FRCOG,MD,FABOG Director of National Centre for Infectious.
Newborn screening (NBS) is a simple procedure to find out if your baby has a congenital metabolic disorder that may lead to mental retardation and even.
Treuman Katz Center for Pediatric Bioethics Conference Banking Biological Samples for Pediatric Research Jeffrey R. Botkin, M.D., M.P.H. Professor.
EMGO Institute for Health and Care Research Quality of Care Martina Cornel, MD, PhD Professor of community genetics & public health genomics Genetic screening.
Social Science, Public Engagement and Genetic Databases: Lessons from Generation Scotland Sarah Cunningham-Burley and Gill Haddow University of Edinburgh.
Care.data: listening to you Robin Burgess Regional Head of Intelligence
DR CHIDI V NWENEKA EXECUTIVE DIRECTOR AFRICAN AIDS VACCINE PARTNERSHIP AAVP and the Promotion of HIV Vaccines in Africa: Supporting Career Development.
Advocating for a 2 nd Physical Education Credit in Secondary Schools Jeannie Larocque, RN, BScN Public Health Nurse Niagara Region Public Health Department.
Electronic Health Records Dimitar Hristovski, Ph.D. Institute of Biomedical Informatics.
Future Use of Stored Samples & Data and the NIH Policy on GWAS and dbGaP NIAID/DAIDS Dione Washington, M.S. -- ProPEP Sudha Srinivasan, Ph.D.-- TRP Tanisha.
Impact Seminar Resilience Development Madrid, 8 & 9 February 2010 Magda Rooze MA/MBA director Impact Madrid, 8 February 2010 GUIDELINES.
Screening Puja Myles
Pregnancy & Newborn Screening Developments. What is screening? Screening is: “a public health service in which members of a defined population, who do.
I have no relevant financial relationships with the manufacturers of any commercial products and/or provider of commercial services discussed in this CME.
NEWBORN SCREENING SAVE YOUR BABY from MENTAL RETARDATION ZHALLENE MICHELLE E. SANCHEZ.
Practical aspects of implementing neonatal screening programmes EURORDIS conference Dubrovnik, 31 May 2013 Martina C Cornel Professor of Community Genetics.
NEWBORN BLOODSPOT - IMPROVING PRACTICE. Screening Tests Offered from 4 th Oct 2010: Phenylketonuria (PKU) Congenital Hypothyroidism (CHT)
Next generation genomics: translation into clinically useful applications in health care Prof.dr. Martina Cornel
Retention period(s) of samples/data Many jurisdictions, as well as hospitals and institutions, mandate retention periods for medical or research-related.
EMGO Institute for Health and Care Research Quality of Care Martina Cornel, MD, PhD Improving test properties for neonatal cystic fibrosis screening in.
EMGO Institute for Health and Care Research Quality of Care Martina Cornel, MD, PhD Professor of community genetics & public health genomics On behalf.
Shubhangi Arora1; Eden Haverfield2; Gabriele Richard2; Susanne B
Scientific and Scholarly Validity
primary and secondary use of dried blood spots
Draft Primary Care Strategy
Detection of heterozygotes
Congenital Anomalies Register -Of What Value?
Prof.dr. Martina C Cornel
Relationships and Sexuality Education (RSE) Information for Parents
What to screen for and when? 18th January 2014 PACITA Lisbon
Martina C. Cornel, J. M. Friedman, A. J. Goldenberg, K. J. Lister, K
Genetic Research in Addicted Individuals and their Families
Community Participation in Research
Research on human biological materials: Lithuanian perspective
On behalf of the Tender NBS team
Professor of Community Genetics and Public Health Genomics
Sierra Leone NPHA: CHAMPS
Comparison of the study findings: Male & female
Nina Barakzai November 2017
NEWBORN SCREENING IN THE UK
Newborn screening Dr Jim Bonham Clinical Director
Catherine Comiskey and Karen Galligan Date 24h /10/2017
Newborn screening and the future – Where do we go from here?
General Data Protection Regulation
Preliminary Draft 5 Year Action Plan HIV, Hepatitis C, and STIs
Information for Patients Please return to reception
Data Access and Stewardship
Practical Guidance on the Use of Social Media for Recruitment
Newborn Bloodspot Screening: bringing it under the Screening Umbrella
Introduction to public health surveillance
care.data: listening to you
Blood borne viral hepatitis action in Wales

Great North Care Record: What people say about data
‘Data ethics and bio-banking’
Presentation transcript:

Storing dried blood spots in NL Neonatal screening: Storing dried blood spots in NL 27th Oct 2016 Dublin Ireland Martina Cornel, MD, PhD Professor of community genetics & public health genomics Community Genetics, Dept Clinical Genetics

Neonatal screening in the Netherlands Starting 1974 with PKU (nationwide) 1981 Congenital hypothyroidism (nationwide) 1987 PhD on Congenital Adrenal Hyperplasia 2002 Nationwide CAH Source: 40 years of NBS in NL

Leftover cards? Some laboratories discarded them shortly after completion of the analyzes due to lack of storage space, some kept all cards for an indefinite period. In 1993 the Netherlands Society of Clinical Genetics requested to the LBCs to keep all cards for a long time, eg. five years, aiming for further scientific research. RIVM was regarded as a suitable location. No further demands were formulated concerning the storage conditions, such as annealing temperature and humidity. After consultation with the RIVM the LBCs agreed to the request. Actually, it was not clear who had the reponsibility over the cards. LBCs = national screening committees – per disorder (PKU, CHT)

Fireworks disaster Enschede 13th May 2000 Children amongst 23 victims Identification? Heelprick cards? -> discussion in media undermining trust

Dried bloodspots for identification? DBS card collection was suggested as a possible means of identification cards were not used journalists took the RIVM to task on informed consent, privacy and especially transparency, as parents were unaware that the cards had been stored

Response Information in five national newspapers Parents withdrew about 550 cards New regulations on who the administrator would be, how to use the cards for research, five years retention

Big Brother Award On the left dr. J. G. Loeber (head reference laboratory) and on the right dr. D. Ruwaard (Sector Director of Health) who on behalf of the RIVMt have received the Big Brother Award 2002 awarded by the Foundation Bits of Freedom.

Current policy The current policy was implemented in 2002: DBS are kept for 1 year for the purposes of the screening program (including quality control), followed by optional storage for 4 years to enable anonymous ‘secondary use’ such as prevalence research, adding up to a maximum storage length of 5 years. tick box on the DBS card to opt out

Neonatal screening – opt out for research

Primary and secondary use??? First of all: identify infants with diseases in whom timely treatment can prevent irreversible damage to health Secondary use: given the dynamics of biotechnology (including genomics): investigate potentially new heelprick conditions Other (public health) research Diagnosis in individual child at later stage: congenital CMV? Identify victims

Research for potential new NBS conditions Can tests, available in clinic, be developped for screening purposes? (High througput, extremely high sensitivity & specificity) (Pompe)

Research for potential new NBS conditions Frequency of MCADD?

Research for other purposes? A similar long term study question: Did HIV occur decades ago?

HIV prevalence in the UK: 1990-2002.

Primary and secondary use??? First of all: identify infants with diseases in whom timely treatment can prevent irreversible damage to health Second: given the dynamics of biotechnology (including genomics): investigate potentially new heelprick conditions Other (public health) research Diagnosis in individual child at later stage: congenital CMV?

Does this child have congenital CMV? CMV is the leading cause of congenital infection in most developed countries, with a frequency of 0.4%–2.3% of live births causes congenital sensory hearing loss and delayed mental development most of those neonates are asymptomatic extraction of CMV DNA from dried blood spots on filter paper … allows the diagnosis of congenital CMV infection Yamagishi J. Med. Virol. 78:923–925, 2006.

Primary and secondary use??? First of all: identify infants with diseases in whom timely treatment can prevent irreversible damage to health Second: given the dynamics of biotechnology (including genomics): investigate potentially new heelprick conditions Other (public health) research Diagnosis in individual child at later stage: congenital CMV? Identify victims

Soon after the new policy came into effect Scientists wanted to keep cards longer: Prevalence/epidemiological studies and specifically allele frequencies and genetic drift, Identification, Screening in later phases of life on stored cards (although the implied linking to health record was not explicitly mentioned) LP ten Kate et al. Medisch Contact 2005

A New Vision: From Population Health Screening to Biological Resource for Research “Another possibility mentioned is to keep an entire year’s worth of cards, in order to later, perhaps in thirty years, study the genetic drift in the population.” Contact between Forum Biotech and Neonatal Screening Committee of the Centre for Population Screening and Ministry: Issues raised: Uses for 1, Prevalence/epidemiological studies and specifically allele frequencies and genetic drift, 2 Identification, 3) Screening in later phases of life on stored cards (although the implied linking to health record was not explicitly mentioned) Such a collection should in theory not be managed by the government nor any governmental body. Danish model referred to but not American lawsuits Optimal is at least 80 years storage 19

Survey: support if transparent! Survey link posted on the Nine Months Fair website Feb 10th - Mar 1st, 2011. Van Teeffelen/ Douglas/Van El @VUMC Likert scales EMGO Instituut - Care and Prevention 20

Etiology but also identify victims – many “fully agree” NB companies involved in test development – less support

Primary and secondary use: conclusion First of all: identify infants with diseases in whom timely treatment can prevent irreversible damage to health Second: New heelprick conditions Other (public health) research Diagnosis in individual child Identify victims Parental support is high Transparency needed

How to move forward? Involve all stakeholders Represent parents of healthy infants and affected infants Similar to biobanks? BBMRI? Models have been proposed in literature Community Values Advisory Board Participant Association to select a Participant Board

Thank you!